Literature DB >> 1576060

Inhaled histamine increases the rate of absorption of sodium cromoglycate from the lung.

R Richards1, C Fowler, S Simpson, A G Renwick, S T Holgate.   

Abstract

Since many factors may alter lung epithelial permeability (LEP) to water soluble molecules, the effect of histamine on the absorption and clearance of inhaled sodium cromoglycate was examined in seven mildly asthmatic patients with hyperresponsive airways and eight normal subjects. The subjects underwent histamine challenge to determine the provocative concentration of histamine required to reduce the forced expiratory volume in one second (FEV1) by 20% (PC20) from baseline. On two further visits they inhaled either saline placebo or histamine and 5 min later inhaled an aerosol containing sodium cromoglycate. Measurements of FEV1 were made and blood samples taken for analysis of plasma sodium cromoglycate concentration at intervals for 3 h. In the asthmatic group histamine inhalation led to a 24 +/- 4% reduction in FEV1 but had no effect on the normal subjects. When compared with inhaled saline, histamine increased the initial pulmonary absorption of SCG without influencing the total amount of drug absorbed in both asthmatics and normals. These observations suggest that the pharmacokinetics of inhaled sodium cromoglycate may be altered significantly by inflammatory mediators present at the site of drug absorption from the airways.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1576060      PMCID: PMC1381288          DOI: 10.1111/j.1365-2125.1992.tb04048.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

Review 1.  Pulmonary clearance of 99mTc-DTPA: a noninvasive assessment of epithelial integrity.

Authors:  H O'Brodovich; G Coates
Journal:  Lung       Date:  1987       Impact factor: 2.584

2.  The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration.

Authors:  M G Neale; K Brown; R W Hodder; R M Auty
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

Review 3.  Histamine and its antagonists in asthma.

Authors:  P Rafferty; S T Holgate
Journal:  J Allergy Clin Immunol       Date:  1989-08       Impact factor: 10.793

Review 4.  The relationship between mast cell-mediator release and bronchial reactivity in allergic asthma.

Authors:  P H Howarth; S R Durham; A B Kay; S T Holgate
Journal:  J Allergy Clin Immunol       Date:  1987-11       Impact factor: 10.793

5.  Dose-related effects of pharmacological mediators on tracheal vascular resistance in dogs.

Authors:  L A Laitinen; M A Laitinen; J G Widdicombe
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

6.  A comparison of the quantitative anatomy of the bronchi in normal subjects, in status asthmaticus, in chronic bronchitis, and in emphysema.

Authors:  M S Dunnill; G R Massarella; J A Anderson
Journal:  Thorax       Date:  1969-03       Impact factor: 9.139

7.  Absorption and disposition kinetics of cromolyn sodium and the influence of inhalation technique.

Authors:  R Richards; C R Dickson; A G Renwick; R A Lewis; S T Holgate
Journal:  J Pharmacol Exp Ther       Date:  1987-06       Impact factor: 4.030

8.  Radioaerosol lung clearance in patients with active pulmonary sarcoidosis.

Authors:  M P Jacobs; R P Baughman; J Hughes; M Fernandez-Ulloa
Journal:  Am Rev Respir Dis       Date:  1985-05

9.  Effect of methacholine induced bronchoconstriction on the pulmonary distribution and plasma pharmacokinetics of inhaled sodium cromoglycate in subjects with normal and hyperreactive airways.

Authors:  R Richards; A Haas; S Simpson; A Britten; A Renwick; S Holgate
Journal:  Thorax       Date:  1988-08       Impact factor: 9.139

10.  Histamine receptors and pulmonary epithelial permeability.

Authors:  T B Chan; N Eiser; D Shelton; P J Rees
Journal:  Br J Dis Chest       Date:  1987-07
View more
  1 in total

Review 1.  Pharmacokinetic optimisation of asthma treatment.

Authors:  A M Taburet; B Schmit
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.